Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Morales-Cano, C. Menendez, J. Moral-Sanz, B. Barreira, R. Jimenez, L. Moreno, A. Cogolludo, J. Cortijo, J. Duarte, F. Perez-Vizcaino (Madrid, Granada, Valencia, Spain). The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension. Eur Respir J 2014; 44: Suppl. 58, 2365

Member's Comments

No comment yet.

Related content which might interest you: Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Immune signatures in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Long-term screening for pulmonary hypertension after pulmonary embolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Pulmonary arterial hypertension – A single-centre experience Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Smad1 deficiency and female gender contribute to the development of pulmonary hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 miR-126; link between angiogenesis and exercise intolerance in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Molecular study of genetic modifiers in patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Non-invasive cardiac output assessment in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Endothelial microparticles and progenitor cells in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Characteristics of patients with pulmonary hypertension in end stage renal disease Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014